#AI and #MentalHealth #Stocks to Watch (CSE: $NARA.CN) (NASDAQ: $WAVD)
(NYSE: $AMWL) (NASDAQ: $TALK) @pangenomic @Amwell @talkspace
How Technology Can be a Game Changer in Mental Health
Treatment and AI is Leading the Way
November 21, 2023 - Investorideas.com (www.investorideas.com), a global
investor news source covering health and wellness stocks releases a special report
on breakthrough technologies for mental health, featuring PanGenomic Health
Inc. (CSE: NARA) (AQSE: NARA). PanGenomic
describes itself as ‘’Your smart tech
partner in natural health’ and is using the power of AI to help
revolutionize healing.
Read this article, featuring NARA in full at https://www.investorideas.com/news/2023/technology/11221AI-Mental-Health.asp
The global mental wellness market is anticipated to grow from USD 145.83 billion to USD 280.52 billion in
10 years. The market will experience rapid growth due to the rising awareness
about mental wellness, Major market players are investing extensive capital in
developing therapies, drugs, medical devices, equipment, systems, and
treatments based on research findings to cater to the growing mental wellness
market.
Most medical experts agree we are in a global
mental health crisis and it is only worsening. While some companies turn to traditional
methods including pharmaceuticals to solve the growing problem, others are
looking to revolutionize the way we treat mental health using technology, and
AI is aiming to take the driver’s seat.
PanGenomic Health Inc. (CSE: NARA) (AQSE: NARA), a precision
health company that has developed a self-care digital platform using AI recently announced that its
subsidiary, MUJN Diagnostics Inc. has launched its BDNF (brain-derived
neurotrophic factor) mental health biomarker health assessment service.
More significantly, it has completed its first sale
of the point-of-care test marketed to health clinics in Canada.
From the news: MUJN
Diagnostics Inc. is a wholly-owned subsidiary of PanGenomic Health Inc. and is
focused on developing a decision support system for alternative healthcare
providers. MUJN's Decision Support System is intended to include biomarker
diagnostics, symptom and treatment tracking, and personalized health analytics,
with the goal of empowering healthcare providers and their patients towards
better outcomes.
"Our strategy is to continue to expand MUJN
Diagnostic's health services beyond our initial Vitamin D assessments to
include rapid in-clinic access to a panel of mental health patient
point-of-care biomarker assessments", said Vincent Lum, CEO of MUJN
Diagnostics and Co-Founder of PanGenomic Health. "Our newest product is
the MUJN BDNF Biomarker assessment for mental health and wellness. Changes in
BDNF levels provide important information for health practitioners when
considering treatment options for patients with brain health concerns such as
major depressive disorder."
From the news: Current
clinical research on BDNF has found that:
BDNF plays a significant role in the survival and
development as well as creation of new neurons. BDNF has been shown to be a
critical regulator of neurocognitive functions and impairment of BDNF levels
have been connected to a variety of mental health diseases.
Decrease in the expression of BDNF is seen in many
neurological problems such as Depression, Alzheimer's, Parkinson's,
Huntington's and bipolar disease.
BDNF serum levels are lower in patients with major
depressive disorder compared with those in healthy controls. Pharmacological
treatments often lead to an increase in BDNF levels, which correlates with an
improvement in a patient's mental health condition.
PanGenomic’s current ‘product line includes its
Nustasis AI Platform, MUJN Diagnostics, and the NARA and MindLeap
consumer apps, all designed to complement conventional medicine, and simplify
the path to better health.
According to a June press release; “The
Company is planning to launch Conversational AI on the web based NARA platform
by Q3, followed by a roll out on the NARA app by Q4 of this year.”
A new entry to the public market with an AI
approach to mental health, WaveDancer, Inc. (NASDAQ: WAVD) announced last week that it
has entered into a definitive merger agreement with privately held,
commercial-stage, medical technology company, Firefly Neuroscience, Inc.
(“Firefly”), to combine the companies in an all-stock transaction. The combined
company will focus on continuing to develop and commercialize Firefly’s
Artificial Intelligence driven Brain Network Analytics (BNA™) platform, which
was previously cleared by the U.S. Food and Drug Administration (“FDA”). Upon
closing, which is currently expected in Q1-2024, the combined company is
expected to operate under the name Firefly Neuroscience, Inc., and trade on the
Nasdaq Capital Market.
Describing
Firefly’s Brain Network Analytics (BNA™) platform the news says, “BNA™
is an FDA-cleared, cloud-based, AI-powered platform used to objectively assess
brain function by comparing patient electroencephalograms (EEGs) with a
proprietary database of standardized, high-definition EEGs and behavioral data.
BNA™ is used by psychiatrists and neurologists in the United States to support
the diagnosis of mental illnesses and cognitive disorders; optimize treatment
care pathways; and improve patient compliance to therapy. Real-world clinical
use has shown that when BNA™ is used as part of patient management, patients
showed improved response rates; enhanced therapy compliance; and reduced non-responder
rates and need for medication switching.”
From the news: Jamie Benoit,
Chief Executive Officer and Chairman of WaveDancer, commented, “Following a
strategic review and analysis of our long-term prospects as a publicly-traded
company, the Board determined that this merger is in the best interests of
WaveDancer’s stockholders and an attractive opportunity to realize significant
value as Firefly pursues multiple market opportunities for its BNA™ platform.
Firefly has emerged from the rigorous FDA approval process and its BNA™
platform has been subjected to comprehensive academic peer-review. We believe
these factors contribute to a competitive advantage for Firefly and position it
as a unique public company.”
Harnessing the power of AI for mental health
improvement, Virtual care provider Amwell (NYSE: AMWL) as reported by Behavioral Health ”has its
sights set on using artificial intelligence to bolster its behavioral health
capabilities.”
“The telehealth giant recently launched a system
within its platform that immediately connects patients to a therapist in real
time.”
“After Amwell providers or its AI-backed automated
systems determine the patient needs mental health services, the patient is
queued to see a clinician on the same platform. The move is meant to bridge a
systemic gap in health care: patient activation.”
“Amwell rolled out the system near the beginning of
the quarter. It’s part of the company’s rolling implementation of Converge, a
unified tech platform.”
“Survey data show that
about 42% of Americans who sought mental health care couldn’t get it because of
costs or other barriers, such as lack of proximity to care. This is a dire
roadblock that keeps patients from getting the care they seek, or that is
prescribed to them by primary care providers, who already have access to the
patient.”
Also using technology for mental health, Talkspace
(Nasdaq: TALK) a leading
virtual behavioral healthcare company recently reported third quarter 2023 financial results.
Third Quarter 2023 Key Performance Metrics:
Revenue increased 32% over the prior-year period to $38.6 million,
driven by a 79% year-over-year increase in the B2B revenue categories,
partially offset by a 32% year-over-year consumer revenue decline.
Gross profit increased 29% over the prior-year period to $18.8 million,
and gross margin declined to 48.8% from 49.8% year-over-year, driven by a shift
in revenue mix towards payor.
Operating expenses were $24.0 million, down 30% year-over-year, driven
by a reduction across all of our operating cost categories.
Net loss was $(4.4) million, an improvement from $(18.0) million net
loss in the third quarter of 2022, primarily driven by lower operating expenses
and an increase in revenues.
Talkspace pioneered the ability to text with a
licensed therapist from anywhere and now offers a comprehensive suite of mental
health services from self-guided products to individual and couples therapy, in
addition to psychiatric treatment and medication management. With Talkspace’s
core psychotherapy offering, members are matched with one of thousands of
licensed providers across all 50 states and can choose from a variety of
subscription plans including live video, text or audio chat sessions and/or
asynchronous text messaging.
As technology
evolves, the applications for health and wellness are endless. As PanGenomic Health says –
AI and other technology may become natural health’s ‘smart tech partner’ of the
future.
About Investorideas.com - Big Investing Ideas
Investorideas.com
is a platform for investing ideas. We
publish breaking stock news, stock research, guest posts and create original
top rated investing podcasts, plus sector tag articles featuring up and coming
companies and industry leaders. Investor
Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for
AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and
wellness, mining, oil and gas, sports and water.
Public companies
within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. Disclosure: This tag article
featuring NARA is paid for content (
third party) Learn more about the cost of ticker tag articles and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
Get more tech stocks investor ideas- news, articles, podcasts and stock directories
Get the Health, Wellness and Sustainability Stocks Directory at Investorideas.com - includes vegan and plant-based food stocks
